ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Decreased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 25.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 56,288 shares of the company’s stock after selling 18,959 shares during the quarter. Price T Rowe Associates Inc. MD’s holdings in ImmunityBio were worth $145,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Stephens Inc. AR bought a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $26,000. Cibc World Markets Corp bought a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $35,000. Maia Wealth LLC bought a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $37,000. Schechter Investment Advisors LLC bought a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $38,000. Finally, Mutual Advisors LLC bought a new stake in shares of ImmunityBio in the 4th quarter valued at approximately $41,000. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Price Performance

Shares of IBRX opened at $2.84 on Friday. The company has a market cap of $2.51 billion, a P/E ratio of -3.09 and a beta of 0.33. The stock has a fifty day moving average price of $2.64 and a 200 day moving average price of $3.28. ImmunityBio, Inc. has a 12 month low of $1.83 and a 12 month high of $7.64.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Monday, May 12th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). The company had revenue of $16.52 million during the quarter, compared to analysts’ expectations of $17.50 million. As a group, research analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of ImmunityBio in a report on Monday, May 12th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of ImmunityBio in a research note on Monday, May 12th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $12.19.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.